 | | Vol.8.34 – 1 September, 2020 |
| |
|
|
| Investigators developed an approach to characterize the metabolic regulome of single cells together with their phenotypic identity.
[Nature Biotechnology] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers showed that the frequency of programmed cell death protein 1 (PD-1)+CD8+ T cells relative to that of PD-1+ regulatory T cells in the tumor microenvironment could predict the clinical efficacy of PD-1 blockade therapies and was superior to other predictors, including PD ligand 1 expression or tumor mutational burden.
[Nature Immunology] |
|
|
|
| Investigators report a cause of NK cell deficiency resulting from compound heterozygous mutations in minichromosomal maintenance complex member 10 that impaired NK cell maturation in a child with fatal susceptibility to CMV.
[Journal of Clinical Investigation] |
|
|
|
| Researchers analyzed exomes, transcriptomes, and low pass whole genomes from 167 gallbladder cancers from patients in Korea, India and Chile.
[Nature Communications] |
|
|
|
| Scientists produced and validated a custom reference signature defining 11 non-cancer cell types to estimate relative proportions of infiltration in a pan-central nervous system tumor cohort spanning 80 subtypes.
[Nature Communications] |
|
|
|
| Investigators showed that blocking dipeptidyl‐peptidases using Val‐boroPro triggers a lytic form of cell death in primary human CD4 and CD8 T cells, while other prototypical inflammasome stimuli were not active.
[EMBO Journal] |
|
|
|
| The Cancer Genome Atlas glioblastoma database and other published mRNA profiles were used to analyze the DRD2 and EGFR expression pattern. In vitro and in vivo responses to DRD2 inhibitors were determined using patient derived xenograft glioblastoma models.
[Neuro-Oncology] |
|
|
|
| The authors identified lncRNAs frequently lost or amplified in cancer. Among them, they found amplified lncRNA associated with lung cancer-1 as frequently amplified in lung adenocarcinomas.
[Journal of Cell Biology] |
|
|
|
| A cohort of 1779 CLL patients underwent mutational analysis, and 56 cases were found to have MYD88 mutations, including 38 with L265P mutations and 18 with non-L265P mutations.
[Blood Cancer Journal] |
|
|
|
| 57 formalin-fixed, paraffin-embedded primary melanomas were analysed by immunohistochemical analysis of CD68, CD163, inducible nitric oxide synthase and arginase expression.
[British Journal of Cancer] |
|
|
|
| The authors found that the Pellino ubiquitin E3 ligase was activated by innate pattern-recognition receptors, such as Toll-like receptors, and was highly upregulated in human psoriatic skin lesions and murine psoriasis-like models.
[Experimental and Molecular Medicine] |
|
|
|
| Monocyte cell cultures were treated with LPS alone or associated with Rosiglitazone to analyze cytokine production and gene expression.
[Scientific Reports] |
|
|
|
| Researchers investigated whether rheumatoid arthritis synovial fluid CD19M+CD24hiCD27+ B cells were increased and associated with bone destruction.
[Scientific Reports] |
|  |
|
|
|
| It appears that metformin, at least in part, has an antitumor effect through activation of the 5’ adenosine monophosphate-activated protein kinase (AMPK) signaling pathway.
[Acta Pharmacologica Sinica] |
|
|
|
| The authors highlight state-of-the-art methods such as immune repertoire sequencing, immunoinformatics and immunogenomic engineering and their application towards adaptive immunity.
[iScience] |
|
|
|
|
| Gilead Sciences, Inc. announced an agreement with Jounce Therapeutics, Inc. to exclusively license its JTX-1811 program. JTX-1811 is a monoclonal antibody designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory cells.
[Gilead Sciences, Inc.] |
|
|
|
| The province of Alberta and the Alberta Cancer Foundation said that they were teaming up to invest $15 million to offer the leading edge therapy that sees a patient’s own immune cells genetically reprogrammed to attack cancer cells in their body.
|
|
|
|
|
|
|
|
| | National Research Council – Ottowa, Ontario, Canada |
|
|
|
| | STEMCELL Technologies – Flexible |
|
|
|
| | Princess Margaret Cancer Center – Toronto, Ontario, Canada |
|
|
|
| | Roswell Park Center for Immunotherapy – Buffalo, New York, United States |
|
|
|
| | Oklahoma Medical Research Foundation – Oklahoma City, Oklahoma, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
